{
  "docId": "019de074-559c-76fa-9457-a7d91e9a06c5",
  "docSlug": "15199f0b497c4ef204a0760da27401b3",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 54 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 29,
  "pageCount": 54,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Includes a data table comparing baseline PCT results with Ovaprene PCT results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-559c-76fa-9457-a7d91e9a06c5/29",
  "deckHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5",
  "deckJsonHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5.json",
  "deckAnchorHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.44,
        "x": 0.52,
        "y": 0.24
      },
      "kind": "callout",
      "text": "The PCT Clinical Study Met its Primary Endpoint. Ovaprene prevented the requisite number of sperm from reaching the cervix across all women and all cycles evaluated.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f0680d5-fd03-4939-86e3-c496dc23d295",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.48,
        "x": 0.04,
        "y": 0.43
      },
      "kind": "list",
      "text": "Step 2 (Ongoing) 1 - FDA approval of investigational device exemption (IDE) for pivotal study start – Obtained 4Q-2022 2 – Review and implement additional FDA study design recommendations 3 - Conduct pivotal study – Recruitment initiation mid-2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7884bf42-5a2e-4c49-932c-4b30ceadb9df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.46,
        "x": 0.04,
        "y": 0.32
      },
      "kind": "list",
      "text": "Step 1 (Completed) Postcoital Test (PCT) Clinical Study - Completed 4Q 2019",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cd8b321-2fab-4dfe-a57b-0e994323b5de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.48,
        "x": 0.05,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "Premarket approval (PMA) strategy - The Center for Devices and Radiological Health (CDRH) as lead review division",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2c1c1b3-2dde-448a-87c9-91357ace1115",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.98,
        "x": 0.02,
        "y": 0.83
      },
      "kind": "source-note",
      "text": "1. Anticipated regulatory pathway and timelines. 2. Mauck C., Vincent K. Biology of Reproduction, Volume 103, Issue 2, August 2020, Pages 437-444",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfea0efd-1374-466d-83b1-172cd0f669a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.38,
        "x": 0.55,
        "y": 0.57
      },
      "kind": "table",
      "text": "Mean/Median Progressively Motile Sperm, Standard Deviation, Interquartile Range for Baseline vs Ovaprene PCT's",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bb12603-6d5c-42a5-ac2d-bb148cbb5d4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.46,
        "x": 0.27,
        "y": 0.16
      },
      "kind": "title",
      "text": "Ovaprene - U.S. Regulatory Strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8a540df-f454-4169-aad5-9f3d7bfaa3f0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 54,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "2cf418f8-2568-4e9a-bf9d-f55bdd0bfb9e",
      "evidence": "The deck implies that inaction in women's health has significant consequences",
      "position": 0,
      "objective": "What is the cost of inaction in women's health?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}